Clene

Clene EBIT Growth

The Year-over-Year EBIT Growth of Clene (CLNN) as of Nov 16, 2026 is 33.72 %. In the previous year, Year-over-Year EBIT Growth was 21.15 % — a change of 59.42% (higher).

EBIT Growth

33.72 %

YoY

59.42%

Last updated:

Year-over-Year EBIT Growth of Clene is 2025 33.72 % . Year-over-Year EBIT Growth of Clene was 2024 21.15 % . It decreases by 59.42% higher compared to the previous year.

The Clene EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
-13,453.97 USD
Jan 1, 2019
-4,941.67 USD
Jan 1, 2020
-23.77 USD
Jan 1, 2021
-147.24 USD
Jan 1, 2022
3.14 USD
Jan 1, 2023
7.15 USD
Jan 1, 2024
21.15 USD
Jan 1, 2025
33.72 USD
The Clene EBIT Growth history
YEAREBIT GrowthYoY
33.72 %+59.42%
21.15 %+195.65%
7.15 %+127.87%
3.14 %-102.13%
-147.24 %+519.47%
-23.77 %-99.52%
-4,941.67 %-63.27%
-13,453.97 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc develops therapeutic products for neurodegenerative diseases, focusing on targeting energetic failure as a root cause. Its primary product CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health by enhancing energy production and utilization. The company also develops CNM-ZnAg, a spectrum antiviral and antibacterial agent containing zinc and silver ions for infectious disease treatment and immune support, and CNM-AgZn17, a gel polymer suspension of zinc and silver for wound healing and infectious disease management. These products are intended for clinical development and eventual commercialization in the pharmaceutical market. Clene's target customers are patients suffering from neurodegenerative diseases and infectious conditions requiring antiviral, antibacterial, or wound healing solutions. The company's products aim to address unmet medical needs in these therapeutic areas by leveraging innovative nanocrystal and ion-based technologies. The firm operates within the biopharmaceutical sector, developing treatments that focus on cellular energy processes to provide neuroprotection and remyelination. The company generates revenue through the development and potential future commercialization of its drug candidates. CNM-Au8 targets neurodegenerative diseases by addressing energetic failure, while CNM-ZnAg and CNM-AgZn17 focus on infectious disease treatment and wound healing applications. These products are in clinical development stages, with the company seeking to advance them toward regulatory approval and market entry. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

Year-over-Year EBIT Growth of Clene is 33.72 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Clene since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Clene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Clene

All Key Metrics — Clene